These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 34899721)

  • 1. Targeting Innate Immunity in Breast Cancer Therapy: A Narrative Review.
    Ye Y; Xu C; Chen F; Liu Q; Cheng N
    Front Immunol; 2021; 12():771201. PubMed ID: 34899721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast Cancer Immune Landscape: Interplay Between Systemic and Local Immunity.
    Gerashchenko T; Frolova A; Patysheva M; Fedorov A; Stakheyeva M; Denisov E; Cherdyntseva N
    Adv Biol (Weinh); 2024 Jul; 8(7):e2400140. PubMed ID: 38727796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type I interferon-mediated tumor immunity and its role in immunotherapy.
    Yu R; Zhu B; Chen D
    Cell Mol Life Sci; 2022 Mar; 79(3):191. PubMed ID: 35292881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innate immune cells in the tumor microenvironment.
    Li MO; Wolf N; Raulet DH; Akkari L; Pittet MJ; Rodriguez PC; Kaplan RN; Munitz A; Zhang Z; Cheng S; Bhardwaj N
    Cancer Cell; 2021 Jun; 39(6):725-729. PubMed ID: 34129817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histamine in cancer immunology and immunotherapy. Current status and new perspectives.
    Sarasola MP; Táquez Delgado MA; Nicoud MB; Medina VA
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00778. PubMed ID: 34609067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling.
    Brown MC; Mosaheb MM; Mohme M; McKay ZP; Holl EK; Kastan JP; Yang Y; Beasley GM; Hwang ES; Ashley DM; Bigner DD; Nair SK; Gromeier M
    Nat Commun; 2021 Mar; 12(1):1858. PubMed ID: 33767151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Innate myeloid cells in the tumor microenvironment.
    Duhan V; Smyth MJ
    Curr Opin Immunol; 2021 Apr; 69():18-28. PubMed ID: 33588308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication.
    Burugu S; Asleh-Aburaya K; Nielsen TO
    Breast Cancer; 2017 Jan; 24(1):3-15. PubMed ID: 27138387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression.
    Bruno A; Mortara L; Baci D; Noonan DM; Albini A
    Front Immunol; 2019; 10():771. PubMed ID: 31057536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy.
    Law AM; Lim E; Ormandy CJ; Gallego-Ortega D
    Endocr Relat Cancer; 2017 Apr; 24(4):R123-R144. PubMed ID: 28193698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-33 in Malignancies: Friends or Foes?
    Shen JX; Liu J; Zhang GJ
    Front Immunol; 2018; 9():3051. PubMed ID: 30619376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.
    Zhou G; Sprengers D; Mancham S; Erkens R; Boor PPC; van Beek AA; Doukas M; Noordam L; Campos Carrascosa L; de Ruiter V; van Leeuwen RWF; Polak WG; de Jonge J; Groot Koerkamp B; van Rosmalen B; van Gulik TM; Verheij J; IJzermans JNM; Bruno MJ; Kwekkeboom J
    J Hepatol; 2019 Oct; 71(4):753-762. PubMed ID: 31195061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity.
    Ma HS; Poudel B; Torres ER; Sidhom JW; Robinson TM; Christmas B; Scott B; Cruz K; Woolman S; Wall VZ; Armstrong T; Jaffee EM
    Cancer Immunol Res; 2019 Mar; 7(3):428-442. PubMed ID: 30642833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor microenvironment of human breast cancer, and feline mammary carcinoma as a potential study model.
    Nascimento C; Ferreira F
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188587. PubMed ID: 34237352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies.
    Baxevanis CN; Fortis SP; Perez SA
    Semin Cancer Biol; 2021 Jul; 72():76-89. PubMed ID: 31881337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy.
    Corrales L; Gajewski TF
    Cytokine; 2016 Jan; 77():245-7. PubMed ID: 26315534
    [No Abstract]   [Full Text] [Related]  

  • 17. Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies.
    Shou D; Wen L; Song Z; Yin J; Sun Q; Gong W
    Oncotarget; 2016 Sep; 7(39):64505-64511. PubMed ID: 27542274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Innate lymphoid cells and cancer: Role in tumor progression and inhibition.
    Yuan X; Rasul F; Nashan B; Sun C
    Eur J Immunol; 2021 Sep; 51(9):2188-2205. PubMed ID: 34189723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effect of malaria parasite infection in a murine Lewis lung cancer model through induction of innate and adaptive immunity.
    Chen L; He Z; Qin L; Li Q; Shi X; Zhao S; Chen L; Zhong N; Chen X
    PLoS One; 2011; 6(9):e24407. PubMed ID: 21931708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-Immune Agonist Nanoparticle Therapy Stimulates Type I Interferons to Activate Antigen-Presenting Cells and Induce Antigen-Specific Antitumor Immunity.
    Levy ES; Chang R; Zamecnik CR; Dhariwala MO; Fong L; Desai TA
    Mol Pharm; 2021 Mar; 18(3):1014-1025. PubMed ID: 33541072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.